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Purpose: To compare the aqueous humor levels of proinflammatory and angiogenic factors of diabetic patients with and
without retinopathy.
Methods: Aqueous humor was collected at the start of cataract surgery from diabetic subjects and non-diabetic controls.
The  presence  and  severity  of  diabetic  retinopathy  were  graded  with  fundus  examination.  Levels  of  22  different
inflammatory and angiogenic cytokines and chemokines were compared.
Results: Aqueous humor samples from 47 diabetic patients (20 without retinopathy, 27 with retinopathy) and 24 non-
diabetic controls were included. Interleukin (IL)-2, IL-10, IL-12, interferon-alpha (IFN-α), and tumor necrosis factor
(TNF)-α were measurable in significantly fewer diabetic samples, and where measurable, were at lower levels than in
non-diabetic controls. IL-6 was measurable in significantly more diabetic samples, and the median levels were significantly
higher in the eyes with retinopathy than the eyes without retinopathy and the non-diabetic eyes. The vascular endothelial
growth factor (VEGF) level was significantly higher in the diabetic eyes with and without retinopathy compared to the
non-diabetic  controls.  The  IL-6  level  positively  correlated  with  the  monocyte  chemotactic  protein-1  (CCL2)  and
interleukin-8 (CXCL8) levels and negatively with the TNF-α level. The VEGF level negatively correlated with the IL-12
and TNF-α levels.
Conclusions: The aqueous humor cytokine profile of diabetic patients without retinopathy was similar to that of patients
with diabetic retinopathy. These cytokines may be useful biomarkers for early detection and prognosis of diabetic
retinopathy. Compared to diabetic patients without retinopathy, only the IL-6 and VEGF levels were significantly higher
in diabetic patients with retinopathy.
The role of angiogenic and proinflammatory cytokines in
the  development  of  diabetic  retinopathy  (DR)  has  been
reported by many groups [1–13]. In particular, elevated levels
of  vascular  endothelial  growth  factor  (VEGF)  have  been
observed in eyes with proliferative diabetic retinopathy (PDR)
and diabetic macular edema (DME) [1–4]. Current treatment
strategies  aimed  at  inhibiting  or  reducing  VEGF-related
mechanisms are now either in use or being developed for
treating DME and PDR. In addition to angiogenic factors,
proinflammatory cytokines such as IL-1 and IL-6 have all
been reported to be elevated in DME and PDR [3–8]. Elevated
levels  of  chemokines,  including  interleukin-8  (CXCL8),
interferon gamma-induced protein 10 (IP-10 or CXCL10),
monocyte  chemotactic  protein-1  (MCP-1  or  CCL2),  and
macrophage  inflammatory  protein-1β  (MIP-1β  or  CCL4),
have also been reported in PDR and have been suggested to
play  a  role  in  attracting  and  activating  leukocytes  in
inflammation  [6,9,10].  Current  studies  on  aqueous  humor
cytokines  are  limited  due  to  the  small  volume  of  ocular
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samples and the inability to analyze a comprehensive range
of  cytokines  and  chemokines  together.  Recently,  the
multiplexed  bead  array  assay  has  allowed  simultaneous
quantification of multiple factors in a small volume. However,
to date, only a few studies investigating large combinations of
cytokines or chemokines in DR have been published [13,14].
Most published studies on cytokine profiles have focused
on  eyes  with  PDR  or  DME  [1–15].  Even  in  studies  that
included diabetic patients with mild or no DR, they were often
used in the context as the control group for cases with more
severe DR. However, there is histopathological evidence that
retinal  microangiopathy  occurs  in  diabetic  subjects  well
before the onset of retinal dysfunction and the appearance of
clinically  detectable  retinopathy  [16,17].  Functional  tests
have confirmed sub-clinical retinal and neuronal dysfunction
in diabetic patients without retinopathy [18,19]. In this study,
therefore, we compared the levels of cytokines in aqueous
humor samples of eyes with DR compared to samples from
eyes of diabetic patients without DR and healthy eyes of non-
diabetic  controls.  The  panel  chosen  is  one  of  the  most
comprehensive among published studies in this area, allowing
further  study  of  correlations  and  interactions  between  the
levels of cytokines and chemokines.
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830METHODS
This study was performed in accordance to the tenets of the
Declaration of Helsinki and approved by the local Institutional
Review Board (IRB) of the Singapore National Eye Centre.
Consecutive patients listed for cataract surgery were invited
to  participate.  Diagnosis  of  diabetes  mellitus  was  self-
reported.  Patients  with  any  other  ocular  condition  (e.g.,
glaucoma,  uveitis)  apart  from  diabetic  retinopathy  were
excluded. Informed consent was obtained from each study
subject. The severity of retinopathy in diabetic subjects was
graded with fundus examination at the time of listing and
confirmed  within  one  month  after  surgery  with  dilated
fundoscopic  examination.  None  of  the  patients  developed
macular edema post-op. Blood pressure and fasting blood
glucose were measured before surgery. 47 diabetic and 24
non-diabetic patients were recruited, including 37 males and
34 females. Of the 47 diabetics, 27 had diabetic retinopathy
and  20  had  no  retinopathy.  The  prevalence  of  coexisting
hypertension and cardiovascular disease were also noted.
About 0.1–0.2 ml of aqueous humor was aspirated into a
sterile tuberculin syringe at the beginning of cataract surgery
after paracentesis was performed. Samples were quickly spun
at 300× g for 5 min at 4 °C using a tabletop microcentrifuge
and stored at –80 °C until further analysis.
Cytokine analysis: Bio-Plex ProTM magnetic color-bead-
based multiplex assay (Bio-Rad Laboratories, Inc., Hercules,
CA) was used to measure the concentrations of 22 human
cytokines/chemokines:  Interleukin-1  receptor  antagonist
(IL-1Ra), IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12,
IL-13, IL-17, granulocyte colony-stimulating factor (G-CSF),
granulocyte  macrophage  colony-stimulating  factor  (GM-
CSF),  interferon-gamma  (IFN-γ),  monocyte  chemotactic
protein-1  (CCL2),  macrophage  inflammatory  protein-1β
(MIP-1β  or  CCL4),  interleukin-8  (CXCL8),  monokine
induced by interferon-gamma (MIG or CXCL9), interferon-
gamma-induced  protein  10  (IP-10  or  CXCL10),  tumor
necrosis  factor-alpha  2  (TNF-α),  IFN-α,  and  vascular
endothelial growth factor (VEGF). The assay was conducted
according  to  the  manufacturer’s  instruction.  Thirty-five
microliters  of  aqueous  humor  sample  was  used  in  each
reaction. Fluorescence intensity from the immunoassay was
acquired  and  analyzed  using  the  Bio-PlexTM  200  System
(software version 6.0; Bio-Rad Laboratories).
Concentrations lower than the low limit of detection were
defined as non-measurable.
Statistical analysis: Statistical analysis was performed
using Predictive Analytics SoftWare (PASW) Statistics 18
(IBM Corporation, Armonk, NY). Statistical significance was
accepted at p≤0.05. For categorical variables, the Pearson χ2
and  Fisher’s  Exact  test  analysis  were  performed.  For
numerical  variables  in  parametric  distribution,  one-way
ANOVA analysis was performed. For differences in cytokine
concentrations, the Mann–Whitney U test with the Bonferroni
correction  was  performed.  The  two-tailed,  nonparametric
Spearman method was used to assess the correlation between
variables.
RESULTS
Aqueous  humor  samples  were  obtained  from  47  diabetic
patients (27 DR and 20 no-DR) and 24 non-diabetic controls.
The baseline demographic data are summarized in Table 1.
Grading of the severity of retinopathy at the time of surgery
was  as  follows:  mild  non-proliferative  (NPDR)  in  15,
moderate  NPDR  in  two,  severe  NPDR  in  two,  active
proliferative (PDR) in one, and stable post-PRP (PRP was
completed  at  least  12  months  before  surgery)  in  seven.
Grading of retinopathy was further confirmed with dilated
fundoscopy  within  the  first  month  post-op.  None  of  the
patients had active clinically significant macular edema at the
time of surgery. History of hypertension and cardiovascular
disease  were  recorded.  Blood  pressure  and  fasting  blood
glucose measured at the start of surgery were collated. The
mean age was not significantly different between the three
groups: 64.9 years (22–89 years) among controls, 67.0 years
(50–84 years) among the diabetic patients without retinopathy
(No-DR) group, and 67.4 years (44–86 years) among the
diabetic patients with retinopathy (DR) group.
The level of assayed cytokines and chemokines in each
group is summarized in Table 2. IL-1β, IFN-γ, IL-4, IL-5,
IL-17, and G-CSF were measurable in less than 50% of the
samples from each group and therefore not included in the
subsequent analysis.
Compared  to  non-diabetic  controls,  the  percentage  of
samples  from  the  diabetic  patients  reaching  detectable
concentrations of IL-2, IL-10, IL-12, IFN-α, TNF-α, and GM-
CSF  was  significantly  lower  (Table  3).  The  median
concentrations  of  these  cytokines  were  also  significantly
lower in the DR and no-DR groups compared to the non-
diabetic controls except for GM-CSF. IL-6 and IL-7 were
detectable in a significantly higher percentage of the diabetic
samples  than  in  the  non-diabetic  controls.  The  median
concentration of VEGF was significantly higher in the DR and
no-DR groups compared to the non-diabetic controls. The
median concentration of IL-6, CCL2, and CXCL8 was also
significantly higher in the DR group (but not the no-DR group)
compared to the non-diabetic controls (Table 2). For some
cytokines,  the  concentration  of  individual  sample  in  each
group is shown in Figure 1.
Ten subjects in the DR group had undergone previous
panretinal photocoagulation (PRP). There was no significant
difference in the level of any of the cytokines analyzed when
compared with the remaining 17 subjects in the DR group who
had  never  undergone  PRP.  Similarly,  the  presence  of
hypertension,  cardiovascular  disease,  HbA1C  level,  and
fasting blood glucose at the time of surgery was not associated
with any significant alteration in any of the cytokine levels.
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831IL-6 was found to positively correlate with IL-7, CXCL8,
IL-13, CCL2, and CCL4 in the DR and no-DR groups and
negatively  with  TNF-α  (Table  4).  The  VEGF  level  was
negatively correlated with IL-12 and TNF-α. We did not find
any correlation between IL-6 and VEGF.
DISCUSSION
In the current study, we compared the aqueous humor levels
of cytokines and chemokines between diabetic patients with
and  without  retinopathy  and  non-diabetic  controls.  We
showed that the aqueous humor cytokine profile in diabetic
patients without retinopathy closely mirrors that of patients
with  diabetic  retinopathy  and  is  significantly  different
compared to controls. IL-2, IL-10, IL-12, IFN-α, and TNF-α
were unmeasurable in significantly more diabetic samples,
and where measurable, the median levels were significantly
lower  in  diabetic  patients  with  and  without  retinopathy
compared  to  non-diabetics.  IL-6,  on  the  other  hand,  was
measurable in significantly more diabetic samples compared
to non-diabetic controls. However, the median concentration
was elevated only in those with retinopathy. VEGF levels
were significantly higher in diabetic patients with and without
retinopathy  compared  to  non-diabetic  controls.  These
alterations  in  cytokines  are  likely  responsible  for  the
pathogenesis of early stages of retinal damage due to diabetes.
Understanding  the  role  of  all  relevant  cytokines  in  the
pathogenesis  of  diabetic  retinopathy  is  important  for
developing future therapeutic options.
Researchers have established that VEGF is one of the key
cytokines  responsible  for  the  pathogenesis  of  PDR  and
diabetic  macular  edema  [1–4].  Our  results  demonstrated
progressively  increasing  VEGF  levels  from  non-diabetic
controls to the diabetic patients without retinography group,
with the highest levels in the DR group. These results support
that VEGF plays a significant role in the pathogenesis of DR
well before the proliferative stage.
IL-6 is a multifunctional cytokine with proinflammatory
properties. Elevated levels of IL-6 have been reported in PDR
and  DME  [20–22].  In  addition,  IL-6  can  induce  VEGF
expression. There have been contradictory reports regarding
the correlation between IL-6 and VEGF levels in diabetic
patients’  eyes  [15,20–22].  In  our  study,  IL-6  levels  were
significantly elevated only in eyes with retinopathy, and no
correlation with VEGF levels was demonstrated. Our data
suggest that in earlier stages of nonproliferative DR, the role
of IL-6 may not be directly linked to VEGF. Indeed, IL-6 has
been implicated in the breakdown of the blood-retinal barrier,
which may contribute to the pathogenesis of earlier stages of
nonproliferative diabetic retinopathy [23,24]. In addition, the
correlation of IL-6 with multiple other cytokines suggest that
it is a major driving force in causing the overall cytokine
profile change in the aqueous humor of diabetic patients.
CCL2 and CXCL8 were elevated in eyes with diabetic
retinopathy  (but  not  in  the  diabetic  patients  without
retinography group) compared to non-diabetic controls, in
keeping with reports from previous studies [5–7,9,10,15,25].
In  addition,  we  have  demonstrated  that  IL-6  strongly
correlates with chemokines in the diabetic group (r=0.74 for
CCL2;  r=0.86  for  CXCL8),  indicating  that  the  increased
levels are likely downstream effects of elevated IL-6 seen in
eyes  with  retinopathy.  CCL2  and  CXCL8  are  potent
chemoattractants, in addition to being angiogenic, and are
known  to  mediate  leukocytic  activation  and  adhesion  to
vascular endothelial cells. Such chronic leukocyte-mediated
inflammation in the vascular walls may eventually lead to
capillary occlusion and retinal ischemia.
IL-12 and TNF-α were negatively correlated with the
VEGF level. The decreased level of IL-2, IL-10, IL-12, and
TNF-α in the diabetic group compared to the non-diabetic
controls is likely related to the increased VEGF levels in the
former  group.  IL-10,  IL-12,  and  TNF-α  are  major  innate
immunity mediators that also bridge the adaptive immune
TABLE 1. BASELINE DEMOGRAPHICS OF ALL PATIENTS.
  Groups  
Characteristics DR (n=27) No-DR (n=20) Control (n=24) p-value
Age (years), mean±SD 67.4±10.7 67.0±9.3 64.9±17.5 0.762c
Gender, n (%)
Male 18 (66.7) 8 (40.0) 11 (45.8) 0.146d
Female 9 (33.3) 12 (60.0) 13 (54.2)  
Duration of diabetes (years), rangea 4 - >30 1 - >10 N.A. 0.210d
Hypertension, n (%) 23 (85.2) 15 (75.0) 9 (37.5) 0.005d
Systolic BP 156.8±23.7 146±20.8 146.6±27.6 0.233c
Diastolic BP 73.8±13.0 74.3±11.3 78.5±13.2 0.400c
CVD, n (%) 9 (33.3) 6 (30.0) 2 (8.3) 0.110d
Blood glucose level (mM)b, mean±SD 9.0±2.8 8.2±2.9 5.1±1.1 0.018c
             a4 groups: 0=No history of diabetes, 1=1–9 years, 2=10–19 years, 3=≥20 years bfasting glucose level cp-value by one-way
        ANOVA dp-value by Pearson χ2 DR=Diabetic with retinopathy; No-DR=Diabetic with no retinopathy; BP=Blood pressure;
        CVD=Cardiovascular disease; SD=Standard deviation
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833response.  Decreased  IL-12  is  likely  responsible  for  the
decrease in IL-2 in the diabetic patients. We hypothesize that
low concentrations of these cytokines in non-diabetic eyes
provide an “immune vigilant” protection against potential
assault. Disruption of such immune homeostasis is likely to
be responsible for some of the pathological changes seen in
diabetic eyes.
We also found reduced levels of IFN-α and GM-CSF in
diabetic  subjects  compared  to  controls.  IFN-α  is  a  potent
angiogenic inhibitor and has been shown to be effective in
treating vascular tumors. Two pilot studies have suggested
IFN-α may have a role in the regression of PDR and protect
against retinal hemorrhage [26,27]. Our current results of
reduced IFN-α levels in diabetic subjects further supports that
this  cytokine  may  have  a  protective  role  against  retinal
damage  in  diabetes.  GM-CSF  has  been  implicated  in  the
retinal damage in uveitis [28]. This cytokine is an important
regulator  of  macrophage,  granulocyte,  and  dendritic  cell
behavior and function. TNF-α and IFN-γ have been shown to
regulate GM-CSF production in retinal pigment epithelial
cells. However, there is limited understanding of GM-CSF’s
role in the pathogenesis of diabetic retinopathy.
Cytokine changes associated with diabetic retinopathy
have been studied in serum [4], tears, vitreous [1–13], and
aqueous humor [11,15,20,25]. More changes were observed
in the vitreous as it closely reflects the pathological changes
of the retina. In contrast to serum and tears, aqueous humor is
likely  to  be  a  more  accurate  reflection  of  the  intraocular
milieu. The aqueous humor levels of VEGF and IL-6 have
been  compared  with  vitreous  levels  and  were  found  to
correlate  strongly  in  diabetic  retinopathy  patients  [20].
Furthermore, aqueous humor is readily harvested as part of
routine  cataract  surgery,  thus  allowing  the  opportunity  to
study a larger number of subjects.
There are limitations to our study. These include the
variable duration of diabetes and glycemic control and lack of
information  regarding  other  medical  conditions.  Some
patients had received panretinal laser. However, there was no
significant  difference  in  any  of  the  cytokine  levels  when
patients  in  this  group  were  separately  compared  with  the
remaining  patients  in  the  DR  group.  The  levels  of  some
cytokines showed large variations. We attempted to mitigate
the large range by including in the analysis only cytokines that
were measurable in at least 50% of controls. Furthermore,
whether  treatment  for  diabetes  may  alter  aqueous  humor
cytokine levels is not known. In addition, as serum was not
collected, we were not able to study the correlating serum
levels of the cytokines reported. These cytokines might be
increased in the serum of patients and enter the eye through
leaky ocular blood barriers, and are not produced in the eye
or have a function there. However, previous reports have
found that ocular cytokine concentrations correlated poorly
with serum levels [4,20,22]. Lastly, we cannot be certain that
the aqueous cytokine profile from cataract controls would not
differ from eyes without cataract.
In summary, we have demonstrated significant cytokine
alteration in aqueous humor samples from diabetic patients
without  retinopathy.  Despite  the  lack  of  clinically  visible
retinopathy, the cytokine profile of the aqueous humor from
these  eyes  showed  marked  similarity  to  those  with
retinopathy, and was significantly distinct from the control
eyes.  These  results  lend  further  support  that  chronic
TABLE 3. TOTAL NUMBER OF MEASURABLE AQUEOUS SAMPLES ANALYZED BY MULTIPLEXED-BEAD ASSAY.
  DR (n=27) No-DR (n=20) Control (n=24)   p-valueb
Cytokines %> LODa %> LODa %> LODa LODa DR and No-DR control
IL-2 2/27 0/20 14/24 1.6 0.000
IL-13 17/27 8/20 17/24 0.7 0.153
IL-6 20/27 9/20 7/24 2.6 0.009
IL-10 8/27 5/20 18/24 0.3 0.000
IL-12 0/27 1/20 16/24 3.5 0.000
TNF-α 0/27 0/20 13/24 6 0.000
IL-1Rα 12/14 11/11 8/14 5.5 0.21
IFN-α 10/27 5/19 16/24 4.3 0.005
CCL2 27/27 20/20 24/24 1.1 -
CCL4 27/27 19/20 24/24 2.4 1.000
CXCL8 25/27 18/20 21/24 1 0.682
CXCL9 13/27 9/19 21/24 1.2 0.001
CXCL10 19/27 13/20 23/24 6.1 0.008
IL-7 19/27 15/20 10/24 1.1 0.012
GM-CSF 8/27 6/20 17/24 2.2 0.001
VEGF 14/14 11/11 14/14 3.1 0.680
        DR=Diabetic with retinopathy; No-DR=Diabetic with no retinopathy; IL=Interleukin; IFN=Interferon; TNF=Tumor necrosis
        factor; GM-CSF=Granulocyte-macrophage colony-stimulating factor; VEGF=Vascular endothelial growth factor. Significant
        difference is accepted at p<0.05. aLow limit of detection (pg/ml); bp-value calculated using Pearson's Chi Square and Fisher's
        Exact test for %>LOD.
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834Figure 1. Scatter plots showing the distribution levels of IL-2, IL-6, VEGF, IL-10, IL-12, TNF-α, IFN-α, and CCL2 in aqueous humor from
diabetic patients with retinopathy (DR, circles), diabetic patients without retinopathy (No-DR, squares), and non-diabetic controls (Non-
Diabetic, triangles). The Mann–Whitney U test with the Bonferroni adjustment was conducted to compare two groups. Significant difference
was accepted at p<0.05. Solid lines indicate the median.
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835inflammation plays a significant role in the pathogenesis of
diabetic retinopathy, and that such inflammation likely occurs
well before the development of any visible retinopathy. These
cytokines  may  be  future  therapeutic  targets  for  diabetic
retinopathy in addition to VEGF.
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